sorafenib,camrelizumab,rivoceranib
jiangsu hengrui pharmaceuticals,elevar therapeutics,bayer
['sorafenib', 'rivoceranib', 'camrelizumab', 'elevar']
#elevartherapeutics announces #camrelizumab plus #rivoceranib significantly prolonged overall survival and #pfs versus #sorafenib in patients with unresectable #hepatocellularcarcinoma during phase 3 trial, a joint program with #hengruipharma #esmo22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.